{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wewer Albrechtsen NJ"],"funding":["Diabetesforeningen","Danmarks Frie Forskningsfond","European Foundation for the Study of Diabetes","Hjerteforeningen","Novo Nordisk Foundation Center for Protein Research","Novo Nordisk Fonden"],"pagination":["2017-2026"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9545540"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(10)"],"pubmed_abstract":["Aims
Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post-hoc analysis of a 3-year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 diabetes. We previously reported that sacubitril/valsartan combined with a dipeptidyl peptidase-4 inhibitor increases active glucagon-like peptide-1 (GLP-1) in healthy individuals. We now hypothesized that administration of sacubitril/valsartan with or without a dipeptidyl peptidase-4 inhibitor would lower postprandial glucose concentrations (primary outcome) in patients with type 2 diabetes via increased active GLP-1.Methods
We performed a crossover trial in 12 patients with obesit"],"journal":["Diabetes, obesity & metabolism"],"pubmed_title":["Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes."],"pmcid":["PMC9545540"],"funding_grant_id":["NNF18OC0032330","NNF21SA0072746","20‐R141‐A9782‐22172","1052‐00003B","NNF14CC0001","NNF19OC0055001","Nicolai J. Wewer Albrechtsen","PI Matthias Mann","NNF18OC0055001"],"pubmed_authors":["Martinussen C","Rashu EB","Gustafsson F","Holst JJ","Hansen LH","Moller A","Kjeldsen S","Goetze JP","Richter MM","Madsbad S","Wewer Albrechtsen NJ","Gluud LL","Plomgaard P","Bojsen-Moller KN","Deacon CF"],"additional_accession":[]},"is_claimable":false,"name":"Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.","description":"Aims
Sacubitril/valsartan is a neprilysin-inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post-hoc analysis of a 3-year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 diabetes. We previously reported that sacubitril/valsartan combined with a dipeptidyl peptidase-4 inhibitor increases active glucagon-like peptide-1 (GLP-1) in healthy individuals. We now hypothesized that administration of sacubitril/valsartan with or without a dipeptidyl peptidase-4 inhibitor would lower postprandial glucose concentrations (primary outcome) in patients with type 2 diabetes via increased active GLP-1.Methods
We performed a crossover trial in 12 patients with obesit","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-06-01T02:10:02.665Z","creation":"2025-02-19T01:28:21.564Z"},"accession":"S-EPMC9545540","cross_references":{"pubmed":["35676803"],"doi":["10.1111/dom.14789"]}}